Drug intelligence / Profile preview

Terepril

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Terepril is an anti-PD-1 monoclonal antibody that functions as an antitumor therapy for various malignancies. It is designed to modulate the immune system to fight cancer. A reported side effect during treatment with Terepril monoclonal antibody is acquired perforating dermatosis.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on Terepril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terepril.

Explore the full profile